MET Inhibition in Advanced NSCLC: Molecular Testing for METex14 and Emerging Options

Get up to date on testing for METex14 and incorporating selective MET inhibitors into the care of your patients with METex14-altered NSCLC with an on-demand Webcast and downloadable slides from a live Webinar, video roundtables, podcasts, and expert-authored commentaries.

D. Ross Camidge, MD, PhD
person default
Luis Paz-Ares, MD, PhD
Karen L. Reckamp, MD, MS

Downloadable Slidesets

Download these slides for expert insights on MET as a new molecular target critical to the care of patients with lung cancer, including guidance on testing for MET exon 14 skipping mutations.

person default Luis Paz-Ares, MD, PhD Released: May 29, 2020

Download these slides for expert insights on MET-targeted therapies in development for MET-altered NSCLC, including tepotinib for METex14 mutation–positive disease.

Karen L. Reckamp, MD, MS Released: May 29, 2020

Download these slides for expert insights on MET-targeted therapies in development for MET-altered NSCLC, including capmatinib for METex14 mutation–positive disease.

D. Ross Camidge, MD, PhD Released: May 29, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by an independent grant from the Healthcare business of
Merck KGaA

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?